GDF15 promotes prostate cancer bone metastasis and colonization through osteoblastic CCL2 and RANKL activation

Jawed Akhtar Siddiqui1,2, Parthasarathy Seshacharyulu3, Sakthivel Muniyan4, Ramesh Pothuraju1, Parvez Khan1, Raghupathy Vengoji1, Sanjib Chaudhary1, Shailendra Kumar Maurya1, Subodh Mukund Lele2, Maneesh Jain1,3, Kaustubh Datta1,4, Mohd Wasim Nasser1,3,5 and Surinder Kumar Batra1,3,4,6

INTRODUCTION
Prostate cancer (PCa), the most common malignant tumor in men, is the second leading cause of cancer deaths in males worldwide. Patients with advanced PCa frequently exhibit distant metastasis, with bone being the preferential site in nearly 90% of metastatic PCa patients. Skeletal metastasis is one of the leading causes of mortality in PCa patients. Although the 5-year survival rate of advanced PCa patients without bone metastasis is nearly 60%, it substantially decreases to 3% in the presence of bone metastases. PCa bone metastasis is accompanied by skeletal-associated complications such as hypercalcemia, intense pain in the bone, bone fractures, and spinal cord compression. The treatment options for PCA-bone metastasis mostly focus on tumor growth and management of pain; hence, the most advanced disease remains incurable.

Bone is an extremely dynamic organ that undergoes continuous remodeling. The bone microenvironment comprises osteoclasts and osteoblasts that function to resorb and mineralize (form new) bone, respectively. The activities of these two cell populations are tightly coupled to balance bone turnover. Osteoblasts and osteoclasts originate from mesenchymal and hematopoietic stem cells, respectively. The bone microenvironment regularly secretes factors for bone maintenance that inadvertently provide a fertile environment for the establishment and growth of tumors within the bone, leading to a vicious cycle. On the basis of radiological appearance, bone metastatic lesions can be classified as osteolytic, osteoblastic, or mixed. Bone metastases in PCa are osteoblastic in nature, characterized by the net formation of new bone of poor mechanical quality but featuring high levels of markers of bone resorption/osteoclast activity.

Transforming growth factor-β (TGF-β) is well known to support PCa bone metastases. Growth differentiation factor-15 (GDF15), also known as MIC-1, is a member of the TGF-β/bone morphogenetic protein superfamily. Physiologically, GDF15 has a major role in prenatal development; the regulation of growth, cartilage and bone formation; and cellular responses to inflammation and stress. In adults, GDF15 facilitates tissue repair after acute injuries. GDF15, which is overexpressed in various malignancies, including PCa, is a potential serum marker in different types of cancers and contributes to tumor development and metastasis. High serum GDF15 levels have been observed in patients with bone metastasis. Glial-derived neurotrophic factor receptor alpha-like (GFRAL) was recently identified as a receptor for GDF15. GFRAL binds to the coreceptor RET (a tyrosine-protein kinase) after binding with GDF15. GFRAL expression seems to be primarily confined to the central nervous system and mediates the anorectic effects of GDF15. However, the presence and role of this GDF15/GFRAL/RET axis in PCa progression and bone metastasis remain obscure. Here, we provide preclinical and clinical evidence to establish the role of PCa-secreted GDF15 in bone metastasis and reveal the mechanism underlying GDF15-mediated osteomac recruitment and alteration of the bone microenvironment.

© The Author(s) 2022

Received: 18 July 2020 Revised: 27 August 2021 Accepted: 12 September 2021
Published online: 20 January 2022
RESULTS

GDF15 promotes PCa bone metastasis
To determine the clinical significance of GDF15 expression, six Oncomine datasets were evaluated. These datasets showed that GDF15 is overexpressed in PCa patients compared to healthy subjects (Fig. S1a). We further analyzed the TCGA database for GDF15 expression and observed significant upregulation of GDF15 in PCa patients and further increased GDF15 expression in metastatic PCa patients (Fig. S1b and S1c). Next, we examined GDF15 expression in a PCa tissue microarray (TMA), which revealed higher staining of GDF15 in prostate adenocarcinoma than in normal prostate samples and increased expression with disease progression (Fig. S1d). We found similar increases in the expression of GDF15 at both the protein and mRNA levels in a panel of human PCa cells compared to normal immortalized RWPE1 cells (Fig. 1a and b).

Previously, we showed that overexpression of GDF15 enhances the proliferation, migration, and anchorage-independent growth of PCa cells. The PC3 cell line, which has low GDF15 expression, was used as a model to evaluate the functional role of GDF15 in PCa bone metastasis. PC3 cell lines stably expressing doxycycline-inducible GDF15-luciferase or control vector-luciferase (PC3-GDF15-Luc[i] or PC3-Luc[i]) were generated (Fig. 1c) and injected intracardially into male nude mice. Metastatic lesions were visualized via IVIS imaging (Fig. 1d). As shown by ex vivo bioluminescent imaging, PCa cells overexpressing GDF15 exhibited widespread skeletal metastasis (in the hind limbs, forelimbs, spinal cord, and ribs with sternum) after one month of inoculation compared to that of control PC3-Luc(i) cells (Fig. 1e). Mice inoculated with PC3-GDF15(i) cells showed declines in their body weight, while those injected with PC3-Luc(i) cells did not (Fig. S1e). After decalcification, the excisedibiae were processed and examined for histopathological changes and metastatic lesions. H&E staining of tibial sections showed tumor-induced cortical bone deterioration in PC3-GDF15(i)-injected mice (Fig. 1f). Next, we stained the bone sections with tartrate-resistant acid phosphatase (TRAP) to determine the bone resorption capacity of mice with PCa overexpressing GDF15. PC3-GDF15(i)-injected mice exhibited more TRAP-positive cells (osteoclasts) and staining with cathepsin K (a marker of functional osteoclasts) than PC3-Luc(i)-implanted mice (Fig. 1f). PC3-GDF15(i)-injected mice also showed more Ki67 staining than PC3-Luc(i)-implanted mice (Fig. 1f). To examine the involvement of GDF15 in PCa-mediated bone turnover, we measured serum P1NP levels, which reflect the degree of bone formation and bone resorption, respectively. PC3-GDF15(i)-injected mice exhibited significantly higher serum CTX and P1NP than PC3-Luc(i)-injected mice (Fig. 1g). Together, these findings strongly suggest that GDF15 overexpression in PCa cells promotes skeletal metastasis.

PCa-GDF15 modulates the bone microenvironment and favors tumor growth in bone
To define the role of GDF15 in PCa-mediated modulation of the bone microenvironment, we next generated PCa cell lines (LNCaP C-81 and C4-2B) with GDF15 knockout (KO) using the CRISPR-Cas9 system. Western blot analysis confirmed the complete knockout of GDF15 in LNCaP C-81 and C4-2B cell lines (Fig. 2a). C4-2B (parental and GDF15 KO) PCa cells were inoculated into the tibiae of nude mice. Higher bone destruction was seen in C4-2B-injected tibiae than in PBS control-injected tibiae; however, the deletion of GDF15 prevented bone destruction from PCa, as shown by 3D reconstruction of images obtained from the high-resolution µ-CT analysis of trabecular bone (Fig. 2b). Next, we examined alterations in bone mineral density (BMD) in the tibiae of animals injected with PBS, C4-2B, and C4-2B (GDF15 KO) cells. The BMD was significantly lower in C4-2B cell-injected tibiae than in contralateral nontumor control tibiae; however, deletion of GDF15 did not decrease BMD (Fig. 2b). C4-2B-injected mice showed visible destruction of trabecular bone, while tibiae obtained from the C4-2B (GDF15 KO)-injected mice were comparable to those of PBS-injected control mice (Fig. S2a, Video 1 & Video 2).

We quantified PCa-mediated trabecular deterioration of the tibial epiphyses (sites of the intratibial injections) of C4-2B and C4-2B (GDF15 KO) cell-injected mice at the architectural level by µ-CT analysis. C4-2B-injected mice had significant microarchitectural deterioration, as indicated by reduced bone trabecular volume (BV/TV), trabecular thickness (Tb.Th), connection density (reflecting trabecular connectedness), and trabecular number (Tb.N), and increased trabecular separation (Tb.S). Deletion of GDF15 in C4-2B cells improved bone microarchitectural parameters, such as BV/TV, Tb.Th, connection density, Tb.N and Tb.S, compared to the parameters in GDF15-deficient mice (Figs. 2c and S2b). Furthermore, IHC analysis of the decalcified tibial sections revealed that tumors formed from C4-2B (GDF15 KO) cells had a lower proliferative index than tumors formed from C4-2B cells, as indicated by fewer Ki67-positive cells (Fig. 2d). The deletion of GDF15 in C4-2B cells also decreased osteoclast formation and function, as reflected by reduced TRAP and cathepsin-K staining (Fig. 2e). Serum analysis of bone turnover markers demonstrated that CTX and P1NP levels were significantly increased in the C4-2B-injected mice compared to the age-matched healthy control mice. In contrast, C4-2B (GDF15 KO)-injected mice showed significantly lower serum CTX and P1NP levels than the C4-2B-injected group (Fig. 2f). Furthermore, we examined the expression of mouse-specific GDF15 in the tibiae of C4-2B- and C4-2B (GDF15 KO)-injected mice. Interestingly, no significant changes were observed in mouse GDF15 expression in the bone of C4-2B PCa-injected mice compared to that of PBS-injected or GDF15 KO cell-injected mice (Fig. S2c). Taken together, these findings indicate that silencing GDF15 impairs tumor growth and progression while protecting the bone microenvironment.

GDF15 increases the recruitment of bone macrophages (osteomacs) via CCL2
Bone-resident macrophages, also known as osteomacs, play roles in coordinating normal bone homeostasis and injury healing. Osteomacs have been shown to impact bone metastasis and PCa progression in bone via osteoclast and osteoblast function. Chemokines, particularly C-C family members, affect the development and progression of PCa within the bone microenvironment by modulating the function of bone cells and facilitating the recruitment of macrophages. To determine whether GDF15 regulates the expression of C-C chemokines in bone cells, we assessed the mRNA expression of C-C chemokines (CCL2, CCL3, CCL7, and CCL12) in osteoblasts following treatment with either rhGDF15 or conditioned medium (CM) collected from different PCa cells. We found that CCL2 was highly expressed among the analyzed chemokines in osteoblasts treated with rhGDF15 (Figs. 3a and S3a-S3c); CCL2 is well known for macrophage recruitment and PCa growth in the bone microenvironment. Similarly, CM from PC3 cells overexpressing GDF15 significantly enhanced CCL2 expression in osteoblasts (Fig. 3b). In contrast, the increase in CCL2 levels was smaller upon treatment with CM from C4-2B (GDF15 KO) cells than upon treatment with CM from C4-2B parental cells. However, C4-2B (GDF15 KO) cell-derived CM supplemented with rhGDF15 induced CCL2 expression to levels comparable to those of parental cells (Fig. 3b). Similar results were observed with CM of the LNCaP C-81 cell line (Fig. S3d). Immunohistochemistry showed significantly higher CCL2 staining in C4-2B-injected tibiae than in either PBS-injected control or C4-2B (GDF15 KO)-injected tibiae (Fig. 3c). In addition, lower serum CCL2 levels were observed in mice injected with GDF15 KO PCa cells than in mice injected with parental PCa cells (Fig. 3d). Mice inoculated with PC3-GDF15(i) cells showed higher serum CCL2 levels than PC3-Luc(i)-injected mice (Fig. 3e). These data suggest...
Fig. 1  GDF15 promotes PCa bone metastasis. a Expression of GDF15 protein in human PCa cell lines as indicated by Western blot analysis. b The expression of GDF15 at the transcriptional level was analyzed by RT-qPCR analysis in human PCa cell lines. c Western blot analyses to determine GDF15 expression in the lysates of PC3-Luc(i) and PC3-GDF15(i) cells after 48 h of doxycycline (Dox) induction. d Representative photographs of mice injected with PC3-Luc(i) and PC3-GDF15(i) cells to detect bone metastasis after Dox treatment at the indicated time points using IVIS imaging. e Representative ex vivo images of excised tissues from different skeletal sites after final in vivo imaging within 10 min of luciferin injection (bioluminescent images of the ribs and sternum, spine, forelimbs, and hind limbs) (left panel) and quantification of the number of skeletal sites with metastasis in mice injected with PC3-Luc(i) and PC3-GDF15(i) (right panel). f Histopathological staining of excised bone sections of PC3-Luc(i)- and PC3-GDF15(i)-injected mice. (Upper panel) Representative H&E staining and TRAP (osteoclast marker) staining of bone. Bone sections were immunostained for cathepsin K (a functional marker for bone resorption) and Ki67 and subjected to corresponding IgG staining. (Lower panel) Quantification of TRAP, cathepsin K and Ki67 staining. Bone marker analysis in serum obtained from PC3-Luc(i)- and PC3-GDF15(i)-injected mice. Scale bar = 400 µm. g Serum CTX and P1NP were measured to assess bone turnover (n = 6 mice/group). The data are given as the mean ± SEM, and P ≤ 0.05 was considered to indicate statistical significance. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the PC3-Luc(i)-injected group.
Fig. 2  PCa-GDF15 modulates the bone microenvironment and favors tumor growth in bone. a Immunoblotting of GDF15 and GDF15 KO clones of the indicated PCa cell lines. b Representative 3D reconstruction of µCT images and bone mineral density BMD/(gm·cm$^{-2}$) of the trabecular region of the tibia at 12 weeks after PBS (control), C4-2B (parental cell) or C4-2B (GDF15 KO) injection in mice. c µCT analysis of trabecular bone in the tibia showing the bone volume fraction (BV/TV)/%, trabecular thickness (Tb.Th/mm), and trabecular number (Tb.N/mm$^{-1}$). All values are expressed as the mean ± SEM. d H&E staining of the excised tibia after decalcification and immunohistochemical staining of tibiae for GDF15 (human), Ki67 and IgG. e TRAP and immunohistochemical (cathepsin K) staining of tibiae. Scale bar = 200 µm. f Serum assessment of CTX and P1NP. The data are given as the mean ± SEM ($n$ = at least 3 mice/group), and $P \leq 0.05$ was considered to indicate statistical significance. *$P < 0.05$, **$P < 0.001$ compared with the control group and #$P < 0.05$, ##$P < 0.01$ compared with the parental (C4-2B)-injected group.
**Fig. 3** GDF15 increases the recruitment of bone macrophages (osteomacs) via CCL2. GDF15 increases the expression of CCL2 in osteoblasts. 

**a** Total RNA was isolated from MCOs treated with rhGDF15 for 48 h and was assessed for CCL2 by RT-qPCR. 

**b** mRNA expression of CCL2 in MCOs after treatment (48 h) with CM from PC3, PC3 cells overexpressing GDF15, C4-2B cells, and C4-2B (GDF15 KO) cells with and without rhGDF15 in vitro. β-Actin was used to normalize the gene expression. 

**c** Immunohistochemical analysis of CCL2/MCP-1 in tibial sections from C4-2B- and C4-2B (GDF15 KO)-injected mice (right panel) quantification. Scale bar = 200 µm. 

**d** CCL2 levels in serum obtained from C4-2B- and C4-2B (GDF15 KO)-injected mice (n = 6 mice/group). 

**e** Serum CCL2 levels in PC3-Luc(i)- and PC3-GDF15(i)-injected mice (n = 6 mice/group). 

**f** Immunohistochemical analysis of CD68 on F4/80+ macrophages in bone sections obtained from C4-2B- and C4-2B (GDF15 KO)-injected tibiae; (right panel) quantification (n = 3 mice/group). Scale bar = 200 µm. The data are presented as the mean ± SEM, and *P < 0.05, ***P < 0.001 compared with the control group and #P < 0.05, ###P < 0.001 compared with the parental (C4-2B)-injected group.
that PCa-secreted GDF15 profoundly increases CCL2 expression in osteoblasts.

CCL2 plays a role in macrophage recruitment and fusion. A high degree of infiltration of F4/80 and CD68-positive macrophages was observed in C4-2B-injected tibiae compared to contralateral control tibiae. However, the infiltration of F4/80 and CD68-positive macrophages in C4-2B (GDF15 KO)-injected tibiae was lower than that in tibiae implanted with parental cells and control tibiae (Fig. 3f). Together, these findings suggest that PCa-secreted GDF15 regulates the expression of CCL2, which in turn serves as a chemoattractant that guides osteomacs to the bone surface.

PCa-secreted GDF15 augments mouse calvarial osteoblast (MCO) activity.

The communication between cancer cells and the bone microenvironment leads to a vicious cycle that induces bone deformities and favors tumor growth in bone. Osteoblasts are the primary bone-forming cells, and PCa patients show high osteoblastic activity. Therefore, we investigated the effect of PCa-secreted GDF15 on MCO differentiation. MCOs were cultured in medium supplemented with increasing concentrations of rhGDF15 or varying proportions of CM from PCa cells (20%, 40%, and 80% in αMEM) under osteoblast-differentiating conditions (in the presence of ascorbic acid and β-glycerophosphate) for 48 h. Treatment with increasing concentrations of CM from cells with high GDF15 (LNCaP C-81 & C4-2B) proportionally increased MCO differentiation after 48 h, as assessed by alkaline phosphatase (Fig. 4a). rhGDF15 also augmented MCO differentiation with increasing concentrations (Fig. 4b and c). Similarly, CM from PC3 cells (which express low endogenous levels of GDF15) engineered to overexpress GDF15 induced greater MCO differentiation than CM from parental cells (Fig. 4d). Next, CM obtained from PCa cells (LNCaP C-81 & C4-2B) with GDF15 deletion inhibited PCa-mediated osteoblast differentiation, and supplementation with rhGDF15 restored osteoblast differentiation (Fig. 4e). These results suggest that GDF15 is crucial for PCa cells to stimulate osteoblast differentiation. We also determined the effect of PCa-secreted GDF15 on osteoblast mineralization, as differentiated MCOs are capable of mineralizing bone matrix. MCO cultures treated with rhGDF15 or CM from LNCaP C-81 and C4-2B cells exhibited robust mineralization, as evidenced by alizarin red-S staining (indicating the osteoclast number) in the bone microenvironment, we examined whether GDF15 released by PCa cells might control osteoclast (OC) formation. We used bone marrow from 4-week-old C57BL/6J mice to generate OCs. Bone marrow macrophages (BMMs) from mice were cultured in the presence of M-CSF and RANKL with and without GDF15 for 7 days to stimulate in vitro OC formation. The addition of rhGDF15 resulted in a significant increase in the number of TRAP-positive multinucleated cells (Fig. 5a).

Furthermore, we performed RT-qPCR analysis for genes associated with the osteoclastogenesis of BMMs. Osteoclast-specific genes such as TRAP, cathepsin K, NFATc1, and carbonic anhydrase were elevated after 7 days of rhGDF15 treatment in the presence of M-CSF and RANKL (Fig. 5b). Since our data suggest that PCa-secreted GDF15 increases C-C chemokine (especially CCL2 and CCL12) expression in osteoblasts, we next sought to examine the effect of CCL2 and CCL12 silencing on GDF15-mediated osteoclastogenesis. CCL12 inhibition had no effect, while CCL2 silencing significantly inhibited the GDF15-mediated increase in TRAP mRNA expression in cultured BMMs (Figs. 5c and S5a and b). Similarly, treatment of BMMs with a mouse-specific anti-CCL2 antibody inhibited the GDF15-mediated upregulation of TRAP expression (Fig. 5d). Similar osteoclastogenic effects were observed following the treatment of BMMs with CM from C4-2B and LNCaP C-81 cells. These effects were abrogated following the deletion of GDF15 and restored upon supplementation of CM with rhGDF15 (Fig. 5e). Together, these data suggest that PCa-secreted GDF15 enhances RANKL-mediated osteoclast differentiation and promotes bone resorption.

GDF15 increases the osteoclastogenic potential of osteoblasts via an increased RANKL signal.

Osteoblasts secrete RANK/receptor activator of NF-κappaB ligand (RANKL) and osteoprotegerin (OPG), which are known to influence osteoclast formation and function. A healthy skeleton depends on a balanced ratio of RANKL and OPG. Treatment with rhGDF15 resulted in the upregulation of RANKL in MCOs, but no effect was observed on OPG expression (Fig. 6a). We next determined whether GDF15 contributes to the PCa-mediated upregulation of RANKL expression in osteoblasts. Treatment of MCOs with CM from PCa cells (C4-2B and LNCaP C-81) led to increased osteoblastic RANKL expression. However, treatment with CM from GDF15-KO PCa cells significantly decreased RANKL expression in MCOs compared to that achieved with parental PCa cell lines, and exogenous supplementation with rhGDF15 rescued RANKL expression in MCOs (Figs. 6b and S6a). Although CM from parental PCa cells (C4-2B and LNCaP C-81) did not alter osteoblastic OPG expression, it did increase the RANKL/OPG ratio compared to that achieved with CM from GDF15-KO PCa cells in the bone microenvironment, reflecting increased resorption and decreased bone mass (Fig. 6b and S6a).

Furthermore, we examined the expression of RANKL and OPG in the tibiae of C4-2B- and C4-2B (GDF15 KO)-injected mice. Interestingly, RANKL expression was higher in the bone of 4-week-old PCa-injected mice than in that of PBS-injected or C4-2B (GDF15 KO)-injected mice (Fig. 6b). Similar to the in vitro observations with MCOs, the expression of OPG was not significantly altered in tibiae injected with C4-2B (GDF15 KO) vs. control tibiae; however, the RANKL/OPG ratio was lower in the tibiae injected with GDF15 KO cells than in those injected with parental cells (Fig. 6b). These results suggest that GDF15 from PCa cells mediates osteoclast formation and bone resorption by modulating the RANKL/OPG system. Furthermore, high alkaline phosphatase levels and osteocalcin-positive cells were observed in
PCa-secreted GDF15 augments osteogenic activity. a PCa factors promote osteoblast differentiation, as measured by alkaline phosphatase assay. MCOs were treated with different proportions of conditioned medium (20%, 40%, and 80%) from LNCaP C-81 and C4-2B cell lines (after 48 h of treatment) and subjected to alkaline phosphatase activity analysis. b Treatment with rhGDF15 for 48 h increased osteoblast differentiation, as determined by measuring alkaline phosphatase activity. c Representative alkaline phosphatase staining of MCOs after 10 days of treatment with the CM of LNCaP C-81 and C4-2B cells and different doses of rhGDF15. d, e Osteoblast differentiation (alkaline phosphatase activity) after 48 h of treatment with CM obtained from PC3 and PC3 cells overexpressing GDF15 and CM from C4-2B and LNCaP C-81 cells. f Assessment of mineralized nodules using alizarin red-S dye staining. MCOs were treated with the control, 20% CM from PCa cell lines, and/or rhGDF15 for 21 days, and the osteoblast differentiation medium was replaced every third day. The left panel shows representative alizarin red-S-stained nodules, and the right panel shows quantification of alizarin red-S staining with cetylpyridinium chloride (CPC) extraction. g MCOs were treated with the control or 20% CM from PCa cell lines and/or rhGDF15 for 72 h in osteoblast differentiation medium. Total RNA was harvested, RT-qPCR for osteogenic genes (alkaline phosphatase: ALP, Runx-2, Col-1a, and osteocalcin) was performed, and gene expression was normalized to that of β-actin. The data represent the mean ± SEM from three independent experiments. P ≤ 0.05 was considered to indicate statistical significance.
the tibiae from C4-2B-injected mice compared to the tibiae from C4-2B GDF15 KO-injected mice, suggesting that the increase in RANKL expression is due to GDF15-mediated osteoblast differentiation. (Fig. 6c)

Recent reports have indicated that GFRAL and RET act as a receptor and coreceptor of GDF15, respectively; however, the presence and role of these receptors in bone cells have not yet been reported. IHC analysis showed that GFRAL and RET were expressed in osteoblasts and osteoclasts.
Fig. 6  GDF15 increases the osteoclastogenic potential of osteoblastic cells via an increased RANKL signal. a MCOs were treated with rhGDF15 for 48 h, and the mRNA expression levels of RANKL and OPG and the ratio of RANKL/OPG expression, representing the degree of osteoclastogenesis, were assessed. b RT–qPCR analyses showing the mRNA expression and ratio of RANKL and OPG in MCOs after treatment with CM from C4-2B cell lines (parental and GDF15 KO). c Immunohistochemistry of ALP and osteocalcin in bone sections obtained from C4-2B- and C4-2B (GDF15 KO)-injected tibiae; (right panel) quantification (n = 3 mice/group). Scale bar = 200 µm. d Immunohistochemistry of GFRAL and RET on the decalcified tibiae of PC3-injected mice. Scale bar = 200 µm. e RNA expression of GFRAL, RET, and Runx2 in MCOs cultured in normal (OB-1) and osteoblast differentiation medium (OB-2) using β-actin as a control. f MCOs were transfected with siRNA targeting GFRAL and control siRNA; after 48 h of transfection, the cell lysates were analyzed for GFRAL, pERK, pAKT, and the respective total forms. β-Actin was used as a loading control. g mRNA expression analyses of ALP, CCL2, and RANKL in MCOs after 48 h of GFRAL siRNA transfection. The data represent the mean ± SEM. P ≤ 0.05 was considered to indicate statistical significance.
Role of GDF15 in prostate cancer bone metastasis
JA Siddiqui et al.

We analyzed all bone parameters through µCT and found that GDF15 is necessary for the PCa-mediated deterioration of trabecular bone. It is well established that bone resorption is a prerequisite for establishing PCa in the bone microenvironment, although the mechanism and relationship to the osteoblastic component remain unclear. Once cancer cells metastasize to bone, the interaction and cross-communication between PCa cells and the bone microenvironment result in a ‘vicious cycle,’ which leads to bone destruction and the growth and survival of cancer cells. Cathespin K-deficient mice exhibit defective bone resorption, which establishes cathespin K as a marker of functional osteoclasts. Our studies demonstrate that PCa-GDF15 modulates cathepsin K expression in the bone microenvironment. These in vivo findings strongly signify the role of GDF15 in PCa-induced osteoclast formation, which provides a niche for the growth of PCa.

Chemokines recruit macrophages and monocytes (precursors of osteoclasts), influencing them toward active bone remodeling for bone matrix resorption. We found that GDF15 increases the levels of C-C family chemokines, including monocyte chemoattractant protein-1 (MCP-1/CC2), a potent chemotactic factor for monocytes in the bone microenvironment. Osteoblastic CCL2 mediates both the catabolic and anabolic action of parathyroid hormones. Several lines of evidence suggest that autocrine and paracrine functions of CCL2 are required for PCa growth and invasion, and inhibition of CCR2 reduces CCL2-mediating PCa growth and invasion. Multiple studies have suggested that CCL2 is responsible for macrophage recruitment and PCa growth in the bone microenvironment. CCL2 promotes macrophage fusion, as demonstrated by the reduced ability of recruited macrophages to form foreign body giant cells in CCL2-null mice. Recently, it has been shown that a distinct population of bone-resident F4/80+ macrophages, termed osteomacs, reside on the endosteal surface and modulate osteoblast activity in normal bone remodeling as well as following injury or damage to the bone. These osteomacs build canopy-like structures around osteoblasts engaged in active remodeling. Osteomacs are distinct from osteoclasts and express common macrophage markers such as F4/80 and CD68, but not TRAP. We found that compared to GDF15-null PCa cells, PCa cells expressing GDF15 increased the numbers of F4/80+ macrophages within mouse tibiae. CD68 is a member of the lysosome-associated membrane protein family and is required for the normal morphology and function of osteoclasts, and CD68−/− mice show impaired osteoclast activity (bone resorption) and increased bone mass. Mouse tibiae injected with GDF15-deleted PCa cells showed fewer CD68+ macrophages in the bone microenvironment. These results suggest that the deletion of GDF15 impaired the ability of PCa to recruit osteomacs and stimulate osteoclast formation. Our findings demonstrate that GDF15 is essential for PCa cells to recruit monocytes/macrophages and that it promotes osteoclast function in bone, probably via the upregulation of CCL2.

GDF15 has been shown to promote or inhibit osteoclast or osteoblast differentiation, depending on the study. Wakchoure et al. found that GDF15 induces osteoclast activation and osteoblast differentiation in bone marrow cells isolated from the long bones of 10–12-week-old C57BL/6J mice. Another study has reported that GDF15 promotes osteoclast differentiation and inhibits osteoblast differentiation of peripheral blood mononuclear cells and human bone marrow-derived mesenchymal stem cells. This observed discrepancy might be due to the use of different cells for osteoblast differentiation. The role of GDF15 in these bone cells is not very clear. Thus, we isolated preosteoblasts from neonatal mouse calvaria and found that GDF15 increased the differentiation and mineralization of osteoblasts. In addition, GDF15 promoted the osteogenic differentiation of bone marrow stromal cells in a heterogeneous culture that contained...
monocytes and macrophages. These results suggest that PCA-secreted GDF15 has osteogenic activity, which facilitates cancer cell proliferation in the bone microenvironment.

In the bone microenvironment, osteoblasts control the development of osteoclasts from macrophages and preosteoclasts by releasing RANKL and the decoy receptor OPG. RANKL binds to its receptor RANK present on macrophages and preosteoclasts and is necessary for osteoclast formation. Altered expression of RANKL and OPG causes an imbalance between bone formation and resorption, leading to osteolytic bone metastasis in PCA. We found for the first time that GDF15 significantly increased the RANKL/OPG ratio (an indicator of bone resorption) in osteoblasts. These results demonstrate an additional indirect role of GDF15 in osteoclastogenesis via the RANKL/OPG axis. GDF15 also contributed to the loss of bone microarchitecture, specifically trabecular bone, and enhanced bone resorption induced by PCA. Notably, it has been reported recently that glial-derived neurotrophic factor receptor alpha-like (GFRAL) acts as a receptor of GDF15. Before GFRAL was identified as a receptor of GDF15, TGF-β receptor types I and II and intracellular SMAD signal transduction protein complexes were thought to mediate the cellular responses of GDF15. In addition, GDF15 promotes actin cytoskeleton rearrangement through activation of FAK-RhoA-GEF-mediated signaling; however, the molecular mechanism is unclear. GFRAL, upon binding with GDF15, interacts with the RET receptor to initiate downstream signaling, such as phosphorylation of ERK and AKT. However, the presence and role of the GDF15/GFRAL/RET axis in PCA progression and metastasis have not yet been reported.

GDF15 secreted from osteocytes promotes PCA growth and invasion, and the presence of GFRAL on PCA cell lines has been reported. In the present study, we demonstrated the expression of GFRAL and RET receptors on bone. The ERK and AKT pathways are highly expressed in osteoblasts and promote their differentiation. GFRAL silencing suggests that GDF15/GFRAL signaling can regulate the differentiation of MCOs by activating the ERK and AKT signaling pathways. Furthermore, silencing GFRAL reduces the GDF15-mediated upregulation of osteoblastic RANKL and CCL2 expression. It is likely that GDF15 binds to and activates GFRAL and RET receptors present on bone cells. However, many questions remain about the role and function of GFRAL and RET receptor signaling in the bone microenvironment, which needs further investigation. In light of these observations, it will be of interest to investigate GFRAL and RET receptor signaling in the context of the cancer-induced bone microenvironment and microarchitectural remodeling, and targeting the GDF15/GFRAL/RET axis could potentially provide a therapeutic avenue for reducing PCA-mediated bone metastasis.

Elevated serum GDF15 has been correlated with increased bone metastasis. It will be interesting to examine whether circulating GDF15 and GDF15 produced locally in the bone microenvironment by tumor or stromal cells play similar or distinct roles in promoting PCA bone metastasis. While it will be of interest to utilize genetically engineered models with GDF15 or the receptors knock out in tumors or stromal compartments, currently available prostate cancer models do not spontaneously metastasize to bone at high frequency. Although TGF-β plays a paradoxical role in tumor development, recent studies have suggested that TGF-β signaling is essential for the development of bone metastasis, and TGF-β-directed therapies inhibit prostate cancer bone metastases. In contrast, GDF15 is a divergent member of the TGF-β superfamily with low sequence conservation with other members of the TGF superfamily, and its signaling through a recently identified novel receptor suggests its unique role in PCA bone metastasis.

In conclusion, our findings suggest that PCA cells secrete GDF15, which modulates bone marrow stromal cells (primarily osteoblasts). Osteoblasts, in turn, secrete RANKL and CCL2 to promote osteoclastogenesis and bone deterioration, favoring the growth of metastatic PCA tumor cells in the bone microenvironment (Fig. 7). Overall, these data, combined with our previously published findings, suggest that GDF15 plays a role in PCA bone metastases through bone microenvironment modulation. It will be of interest to determine the potential of targeting the GDF15/GFRAL/RET axis.
as a therapeutic strategy to prevent bone metastasis and increase the quality of life of PCa patients.

MATERIALS AND METHODS

Animal use and ethics
All in vivo experiments were performed as per the University of Nebraska Medical Center (UNMC) guidelines. Immunocompromised male athymic nude mice were generated and maintained under a breeding and experimental protocol approved by the UNMC Institutional Animal Care and Use Committee (IACUC), as described previously.

Cell line maintenance and preparation of conditioned media from PCa cells
Human PCa cell lines (RWPE1, DU145, and PC3) were originally obtained from the ATCC (Rockville, MD, USA), maintained in a CO2 incubator at 37 °C and routinely tested for STR profiles and mycoplasma contamination. The culture conditions of RWPE1, LNCaP C-81, and C42B PCa cells were as described in our earlier publications. For conditioned medium (CM) preparation, LNCaP C-81, C42B, and PC3 cells (2 × 10^5) were grown overnight in 100 mm culture dishes in cell culture medium. After two washes with phosphate-buffered saline (PBS), the cells were incubated for 48 h in 1% FBS in RPMI medium before collection of the CM.

GDF15 inducible system
GDF15 was overexpressed in the PC3 cell line by using a 3rd generation lentiviral system. We performed dual transduction using rtTA along with a pLV[Tet]-mCherry:T2A:Puro>TRE3G > FLAG/hGDF15/HAT2A:Luciferase or pLV[Tet]-mCherry:T2A:Puro>TRE3G > Luciferase vector obtained from VectorBuilder, TX, both of which also expressed mCherry and luciferase (for quantitation and in vivo imaging). For lentiviral transduction, PC3 cells (1 × 10^6) were seeded in six-well plates. The lentiviral mixture (1 mL) and polybrene were added to each well. After overnight incubation, the transduction medium was replaced with fresh medium. Transduction efficiency was assessed by visualizing the cells for mCherry fluorescence, and the positive cells were sorted with a FACs Aria II (BD Biosciences). They were subsequently transduced with rtTA-containing lentivirus to activate TRE3G via the transactivator Tet3G.

Intracardiac injections of PCa
Intracardiac injections were performed to assess skeletal metastasis, as previously described. Briefly, PC-3-Luc(l) or PC3 GDF15(l) cells (1 × 10^6) were injected into the left ventricles of male athymic nude mice (4–6 weeks old). After the intracardiac injections, the mice were kept on special water (doxycycline, 3.2 g L⁻¹, and sucrose 30 g L⁻¹) to induce GDF15 overexpression. The doxycycline-sucrose solution was changed every 3 to 4 days throughout the experiment. Skeletal metastases were monitored by bioluminescence detection of luciferase-expressing cells with the IVIS system. Bones from all major skeletal sites were harvested after 6 weeks and decalcified in 10% EDTA. Serum was obtained from the collected blood after cardiac puncture at the time of sacrifice to analyze the bone-related markers.

Intratibial injections of PCa
To study the effect of GDF15 deletion on tumor growth, athymic nude male mice (4–6 weeks) were inoculated intratibially with C4-2B and C4-2B (GDF15 KO) cells. Briefly, mice were anesthetized with ketamine and xylazine, and both legs were cleaned with 70% ethanol. Luciferase-labeled PCa cell (C4-2B and C4-2B [GDF15 KO]) suspensions (5 × 10^6 cells in 20 μL) were injected into the proximal part of the tibia using a syringe fitted with a 27 3/8-inch gauge needle. The other tibia was injected with an equal amount of PBS. Bioluminescence imaging and radiography were used to assess the tumor burden in the bone. All animals were sacrificed, and blood and bone were collected for analyses of bone markers and histology.

Micro-computed tomography (μCT) analysis of mouse tibiae
After intratibial injection, μCT analysis of excised tibiae was performed using a Sky Scan 1172 μCT scanner (Sky Scan, Ltd., Belgium). The tibiae were dissected from the mice after euthanasia and cleaned of soft tissue. The samples were scanned at a nominal resolution (pixels) of 9.7 μm. NRECON (Skyscan) was used for the reconstruction of all images. Briefly, the reconstructed data were binarized using a threshold of 79–255. All three-dimensional volumetric analyses of trabecular bone were accomplished using CTAn software (Skyscan). The bone mineral density of trabecular bone was calculated from the binary data based on a calibration curve of calcium hydroxyapatite standards. To maintain consistency in tibial injection sites, we omitted the first 50 slices from the growth plate, after which another 258 slices were selected to analyze the data. The μCT measurements followed the guidelines of Bouxsein et al. Three-dimensional analyses were used to determine the trabecular bone architecture.

Western blot analysis
Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer containing protease and phosphatase inhibitors. The lysates were freeze-thawed, syringe passed, centrifuged at 23 000 r·min⁻¹ for 25 min at 4 °C, subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, and immunoblotted. Primary antibodies against GDF15 (Abcam); GFRAL (Thermo Fisher Scientific); pERK, pAKT, ERK and AKT (Cell Signaling Technology); and β-Actin (Sigma–Aldrich) were used for immunoblotting. The membranes were probed with the respective secondary antibodies for an hour before the expression was captured with enhanced chemiluminescence reagent as previously described.

Culture of calvarial osteoblasts from mice
Mouse calvarial osteoblasts (MCOs) were obtained using a previously published protocol of sequential digestion. Briefly, calvaria from 1- to 2-day-old C57BL/6 J mice (5/6 of both sexes) were pooled after sacrifice by decapitation. After isolation from the skull using a midline incision, the calvaria were subjected to five sequential (10–15 min) enzymatic digestions at 37 °C in a solution containing 0.1% dispase and 0.1% collagenase. The released cells after enzymatic digestion (second to fifth digestions) were collected, centrifuged, and plated in T-25 flasks in α-MEM containing 10% FBS and 1% penicillin/streptomycin (complete growth medium).

Osteoblast differentiation
MCOs were cultured in α-MEM supplemented with 10% FBS, and after reaching 80%–90% confluency, the cells were seeded at a density of 2 × 10⁴ cells/well in 96-well plates. The cells were treated with different concentrations of rhGDF15 and CM from PCa cells for 48 h in osteoblast differentiation medium (α-MEM supplemented with 5% FBS, 10 mmol·L⁻¹ β-glycerophosphate, and 50 mg·mL⁻¹ ascorbic acid). Osteoblast differentiation was assessed by determination of alkaline phosphatase (ALP) activity in cells. ALP activity was measured using p-nitrophenyl phosphate as a substrate and quantitated colorimetrically at 405 nm.

Mineralization of calvarial osteoblasts
Calvarial osteoblasts cultured until they reached 80% confluence were trypsinized and plated in differentiation medium (25 000 cells/well in a 12-well plate) consisting of complete growth medium with ascorbic acid and β-glycerophosphate. The
medium was changed every alternate day for up to 21 days. The treatment group contained a medium similar to that of the GDF15 group. After completion of the experiment, the cells were washed with PBS and fixed with 4% paraformaldehyde in PBS for 15 min. The cells were stained with 40 mmol·L$^{-1}$ (pH 4.5) alizarin red-S for 30 min and then washed with water$^{74}$. Quantification of staining was performed by cetylpyridinium chloride (CPC) extraction as previously described$^{74}$.

Mineralization of bone marrow stromal cells (BMSCs) BMSCs from 4- to 6-week-old male C57BL/6 J mice were isolated and cultured according to a previously published protocol$^{76}$. In brief, the femora and tibiae were excised aseptically, cleaned of soft tissues, and washed in culture medium. Bone marrow was flushed out in 20 mL of α-MEM. The BMSCs were counted and plated (2 x 10$^5$ cells/well) in 12-well plates in culture medium consisting of α-MEM supplemented with 10% FBS, dexamethasone (10$^{-7}$ mol·L$^{-1}$), ascorbic acid (50 mg·mL$^{-1}$), and β-glycerophosphate (10 mmol·L$^{-1}$) in the presence or absence of CM from different PCa cells along with rhGDF15 for 21 days. The old medium was replaced every 48 h. After 21 days, the attached cells were fixed in 4% formaldehyde for 20 min at room temperature and rinsed once in PBS. After fixation, the plates were stained with 40 mmol·L$^{-1}$ alizarin red-S, which stains areas rich in nascent calcium$^{94}$.

RNA interference (siRNA treatment) siRNA-mediated knockdown of GFRAL was performed in MCOs. Briefly, the MCOs were transfected with either target siRNA (SMARTPool, concentration 50 mmol·L$^{-1}$) or control siRNA using ON-TARGET PLUS siRNA reagents (Dharmacon, Illinois, USA) as per the manufacturer’s instructions. The efficacy of GFRAL knockdown was assessed by western blot analysis after 48 h of transfection. For CCL2 and CCL12 knockdown, mouse BMM cultures were transfected as described above, and the cultures were continued for another 5 days with RANKL and MCSF and with or without rhGDF15 (10 ng·mL$^{-1}$). At the end of the experiments, RNA was isolated to determine the TRAP transcript level.

Osteoclast differentiation from mouse bone marrow macrophages (BMMs) Bone marrow cells were isolated from 4-week-old C57BL/6 J mice, as described previously$^{95}$. Briefly, after epiphyses of the bone were removed from the tibia and femur, the marrow cavity was flushed entirely with α-MEM using a sterile 25-gauge needle. Bone marrow macrophages (BMMs) were cultured in α-MEM containing 10% FBS. The cell cultures were incubated with macrophage colony-stimulating factor (M-CSF) (30 ng·mL$^{-1}$) and receptor activator of NF-kappaB ligand (RANKL) (50 ng·mL$^{-1}$) and exposed to various treatments consisting of rhGDF15 (0–100 ng·mL$^{-1}$) and/or 20% CM from PCa cells. GDF15 was added at the start of the culture and at every medium change (every 2 days). After 7 days, cells were collected for mRNA analysis. Osteoclast differentiation was measured by determining the number of cells that had been positively stained by tartrate-resistant acid phosphatase (TRAP). Osteoclasts were identified as TRAP-positive-stained multinuclear cells (fused cells with 3+ nuclei) using light microscopy$^{94}$.

TRAP staining After osteoclast differentiation, cells were fixed with 4% paraformaldehyde in PBS for 30 min at room temperature and stained for TRAP with a Leukocyte Acid Phosphatase Kit (387-A; Sigma–Aldrich) following the manufacturer’s instructions$^{93}$.

RNA isolation and quantitative real-time PCR analysis An RNA isolation kit (Qiagen) was used to isolate the total RNA from different experiments. Total RNA (1 µg) was used for the synthesis of cDNA using random hexamers and TaqMan® Reverse Transcription Reagents. SYBR® Green Master Mix (Roche) was used for quantitative real-time PCR using a Bio–Rad instrument. The relative mRNA expression of genes was calculated using a formula reported previously$^{73}$. β-Actin was used to normalize the expression levels, and the data are presented as the fold changes compared with the levels in the control samples. The details of all primers used in this study are provided in Supplementary Table S1. After PCR amplification, 20 µL of the PCR product was electrophoresed in a 2% agarose gel for conventional PCR assessment.

Serum analyses for CCL2, CTX, and PINP Blood samples were collected by cardiac puncture from the mice after the in vivo experiment. Sera were collected by centrifugation of blood samples at 5 000 × min$^{-1}$ for 10 min. Serum C-terminal telopeptide of collagen (CTX), N-Terminal Propeptide Of Type I Procollagen (PINP) (Immunodiagnostic Systems Inc.) and CCL2 (Invitrogen) were measured by ELISA according to the manufacturer’s instructions.

Immunohistochemistry and histology At the end of the in vivo experiments, the tibiae and femora were harvested, placed in fresh 10% formalin, and decalcified in 10% EDTA before paraffin embedding. Specimens were sectioned (5 µm) and stained with H&E and TRAP (to identify osteoclasts; Acid Phosphatase Leukocyte Kit, Sigma). For IHC of human GDF15, CCL2, ALP, Ki67 and cathepsin K (intratibial experiment), the sections were incubated with primary antibodies overnight at 4 °C and then with a secondary antibody for 30 min at room temperature. An ABC Staining System (Vector Laboratories) was used as described previously$^{77}$. For CD68, F4/80, GFRAL, RET, cathepsin K (intracardiac experiment) and osteocalcin IHC, the sections were incubated with primary antibodies overnight at 4 °C and then with a secondary antibody for 20 min. The sections were counterstained with hematoxylin. These IHC experiments were performed using a Histo-Mouse Max AEC Detection Kit (Invitrogen)$^{95}$. Mouse IgG (Jackson ImmunoResearch Laboratory) was used as a negative control. A similar IHC protocol was adopted for analysis of GDF15 expression in clinical samples. A commercially available prostate tissue microarray (TMA, US Biomax, Rockville) was immunostained with an anti-GDF15 antibody. Semiquantitative scoring ranging from 0-3 was performed by multiplying the staining intensity and percentage of positively scored cells, as reported previously$^{74}$. Quantification of IHC staining was performed with ImageJ software$^{95}$. Details of the antibodies used for immunohistochemistry are listed in Supplementary Table S2.

RNA in situ hybridization assay For in situ hybridization (ISH) of GFRAL, we used a commercially available single-color mouse-specific 20-pair double-Z oligonucleotide probe (NM_205844.3, target region 21186) (Advanced Cell Diagnostics). Briefly, 5-µm decalcified tibia sections from mice were used for ISH. The slides were baked for 1 h at 60 °C, and for deparaffinization, the sections were treated with protease for 30 min at 40 °C. Preheated target probes (GFRAL) were hybridized for 2 h at 40 °C, and then a series of signal amplification and washing steps were performed using a HybEZ Hybridization System. The hybridization signals of the probes were detected by sequential chromogenic reactions using brown chromogens. For detection of GFRAL RNA transcripts, we used a commercially available kit (in situ hybridization with RNAscope®. 2.5 HD Assay-BROWN, RNAscope®$^{75}$. Brightfield images were acquired using a 40x objective.

Statistical analysis Student’s t test or one-way ANOVA was applied to evaluate differences using the GraphPad InStat software program (GraphPad Software, Inc.). P values < 0.05 were considered to indicate
statistical significance. All in vitro assays were repeated a minimum of two times. For in vivo assays, n indicates the number of samples from different mice.

Study approval
All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of UNMC.

ACKNOWLEDGEMENTS
The authors thank Kavita Mallya for her technical help. The authors also acknowledge the University of Nebraska Medical Center small animal imaging facility and tissue science facility for their resources and service. We also would like to thank Jessica Mercer for editing this manuscript. This work and the authors are, in part, supported by grants from the National Institutes of Health (NIH) U01 CA185148, DOD W81XWH-18-1-0308 (SKB), DOD W81XWH-21-1-0640 (JAS), and R01 CA218545, R01 CA241752 (MWN).

AUTHOR CONTRIBUTIONS
JAS and SKB conceived the idea and designed the experiments. SKB supervised the study. JAS performed the study and drafted the manuscript. SM developed the GDF15 KO cell lines. PS, SM, PK, RV, SC, and SKM helped in performing the experiments. SML, MJ, KD, MWN, and SKB helped revise the manuscript and provided scientific feedback. All authors read and approved the final paper.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41413-021-00178-6.

Competing interests: SKB is one of the co-founders of Sanguine Diagnostics and Therapeutics, Inc. The other authors declare no competing interests. The authors have declared that the submitted manuscript is original and is not under consideration by another journal. Every author is aware of and has agreed to the content of this paper.

REFERENCES
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34 (2019).
2. Sartor, O. & de Bono, J. S. Metastatic Prostate Cancer. N. Engl. J. Med. 378, 645–657 (2018).
3. Rubendorf, I. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31, 578–583 (2000).
4. Norgaard, M. et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J. Urol. 184, 162–167 (2010).
5. Tsuruki, S., Park, S. H., Eber, M. R., Peters, C. M. & Shiozawa, Y. Skeletal complications in cancer patients with bone metastases. Int. J. Urol. 23, 825–832 (2016).
6. Siddiqui, J. A. et al. Paracrine systemic regulation and growth factor involvement. Physiol. (Bethesda) 31, 233–245 (2016).
7. Shupp A. B., Kolb A. D., Mukhopadhyay D., Bussard K. M. Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts. Cancers (Basel) 10 (2018).
8. Saad, F. Eastham, J. A. & Smith, M. R. Biochemical markers of bone turnover and progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion. Oncogene 38, 4540–4559 (2019).
9. Tassone, E. et al. KLF4 as a rheostat of osteostilisis and osteogenesis in prostate tumors in the bone. Oncogene 38, 5766–5777 (2019).
10. Brasso, K. et al. Prognostic value of PIPN, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66, 503–513 (2006).
11. Dai, J. et al. Catabolic effects of human PTH (1-34) on bone: partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 36, 159–172 (2005).
12. Li, C. Y. et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J. Bone Min. Res. 18, 1882–1888 (2003).
13. Guise, T. A. The vicious cycle of bone metastases. J. Musculoskelet. Neuronal Interact. 2, 570–572 (2002).
14. Kiviranta, R. et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 36, 159–172 (2005).
15. Siddiqui, J. A. et al. Osteoblastic monocyte chemoattractant protein-1 (MCP-1) mediation of parathyroid hormone’s anabolic actions in bone implies TGF-beta signaling. Bone 143, 115762 (2021).
16. Yu, Y. et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66, 1311–1318 (2006).

SPRINGER NATURE
Role of GDF15 in prostate cancer bone metastasis
JA Siddiqui et al.

46. Siddiqui, J. A. & Partridge, N. C. CCL2/Monocyte chemoattractant protein 1 and parathyroid hormone action on bone. *Front. Endocrinol. (Lausanne)* **8**, 49 (2017).

47. Winkler, I. G. et al. Genetic ablation of CD68 results in mice with increased bone and dysfunctional osteoclasts. *PLoS One* **6**, e25838 (2011).

48. Chang, M. K. et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. *J. Immunol.* **181**, 1232–1244 (2008).

49. Sinko, P. J. et al. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. *Prostate* **69**, 652–661 (2009).

50. Vanhara, P. et al. Growth/differentiation factor-15 inhibits differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease. *Haematologica* **100**, e511–e514 (2015).

51. Winkler, I. G. et al. Growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model. *Bone* **50**, 695–703 (2012).

52. Wakchoure, S. et al. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. *Prostate* **69**, 652–661 (2009).

53. Siddiqui, J. A. et al. A naturally occurring rare analog of quercetin promotes peak bone mass achievement and exerts anabolic effect on osteoporotic bone. *Osteoporos. Int.* **22**, 3013–3027 (2011).

54. Nakai, Y. et al. Ef ﬁ cacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. *Bone Res.* **3**, 7 (2015).

55. Johnsen, H. et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. *Nat. Med.* **13**, 1333–1340 (2007).

56. Tan, M., Wang, Y., Guan, K. & Sun, Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. *Proc. Natl. Acad. Sci. USA* **97**, 109–114 (2000).

57. Xu, J. et al. GDF15/MIC-1 functions as a protective and anhypertrophic factor released from the myocardium in association with SMAD protein activation. *Circ. Res.* **98**, 342–350 (2006).

58. Ge, C., Xiao, G., Jiang, D. & Franceschi, R. T. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. *J. Cell Biol.* **176**, 709–718 (2007).

59. Xiao, G. et al. Bone morphogenic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. *J. Bone Min. Res.* **17**, 101–110 (2002).

60. Xiao, G., Jiang, D., Gopalakrishnan, R. & Franceschi, R. T. Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfal/Runx2. *J. Biol. Chem.* **277**, 36181–36187 (2002).

61. Xiao, G. et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfal1. *J. Biol. Chem.* **275**, 4453–4459 (2000).

62. Mukherjee, A. & Rotwein, P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. *J. Cell Sci.* **122**, 716–726 (2009).

63. Juarez, P. & Guise, T. A. TGF-beta in cancer and bone: implications for treatment of bone metastases. *Bone* **48**, 23–29 (2011).

64. Hu, Z. et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model. *Hum. Gene Ther.* **23**, 871–882 (2012).

65. Wan, X. et al. Effect of transforming growth factor beta (TGF-beta) receptor 1 kinase inhibitor on prostate cancer bone growth. *Bone* **50**, 695–703 (2012).

66. Bootcov, M. R. et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. *Proc. Natl. Acad. Sci. USA* **94**, 11514–11519 (1997).

67. Seshacharyulu, P. et al. FDPS cooperates with PTK7 to promote prostate cancer progression through modulation of small GTPases/akt axis. *Oncogene* **38**, 5265–5280 (2019).

68. Munyan, S. et al. Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling. *Clin. Cancer Res.* **26**, 5720–5734 (2020).

69. Mima, M. et al. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer. *Oncotarget* **6**, 3887–3903 (2015).

70. Park, S. I., Kim, S. J., McCauley, L. K. & Gallicic, G. E. Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. *Curr. Protoc. Pharmac. Chapter* **14**, 15 (2010).

71. Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. *J. Bone Min. Res.* **25**, 1486–1486 (2010).

72. Siddiqui, J. A. et al. Naturally occurring rare analog of quercetin promotes peak bone mass achievement and exerts anabolic effect on osteoporotic bone. *Bone Res.* **22**, 3013–3027 (2011).

73. Pothuraju, R. et al. Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance. *Mol. Cancer* **19**, 37 (2020).

74. Siddiqui, J. A. et al. 8,8’-Biapigeninyl stimulates osteoblast functions and inhibits osteoclast and adipocyte functions: Osteoprotective action of 8,8’-biapigeninyl in ovariectomized mice. *Mol. Cell Endocrinol.* **322**, 256–267 (2010).

75. Trivedi, R. et al. Kaempferol has osteogenic effect in ovariectomized adult Sprague-Dawley rats. *Mol. Cell. Endocrinol.* **289**, 85–93 (2008).

76. Wang, Y. et al. BK ablation attenuates osteoblast bone formation via integrin pathway. *Cell Death Dis.* **10**, 738 (2019).

77. Vengro, R. et al. Matinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRVIII-Met signaling in glioblastoma cells. *J. Exp. Clin. Cancer Res.* **38**, 266 (2019).

78. Wang, F. et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. *J. Mol. Diagn.* **14**, 22–29 (2012).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless otherwise indicated. For anything not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.